Skip to main content

Table 5 Factors associated with HCV service provision at DCRs/SIFs - bi-variate logistic regression

From: Drug consumption rooms (DCRs) as a setting to address hepatitis C – findings from an international online survey

  (1) Provide HCV testing onsite
(n = 32; 665%)
OR (standard error), p-value
(2) Provide liver monitoring or disease management onsite (n = 25; 51%)
OR (standard error), p-value
(3) Provide HCV treatment onsite or planning to provide in near future (n = 10; 20%)
OR (standard error), p-value
Operational
 Country (Netherlands) 0.15* (0.13), 0.02 1.48 (0.37), 0.11 1.39 (0.42), 0.26
 Operated by the government 0.89 (0.58), 0.86 0.53 (0.33), 0.31 1.57 (1.23), 0.57
 Funding from local government 0.55 (0.41), 0.41 0.76 (0.52), 0.69 0.64 (0.53), 0.59
 Co-located with another program 1.38 (0.90), 0.61 1.67 (1.02), 0.40 2.84 (2.50), 0.21
 Stand-alone facility with other services nearby 2.01 (1.51), 0.53 1.17 (0.76), 0.81 0.69 (0.62), 0.68
Staff-Related
 Employing a nurse 2.08 (1.60), 0.34 12.38** (13.92), 0.01 0.70 (0.64), 0.70
 Employing a medical doctor 1.48 (0.98), 0.55 8.00*** (5.66), 0.00 14.58*** (16.41), 0.00
 Employing peer workers 0.88 (0.70), 0.87 0.47 (0.34), 0.29 1.43 (1.31), 0.70
 Higher than median number of paid staff on average day (> 4) 1.20 (0.80), 0.80 1.22 (0.77), 0.75 2.00 (1.62), 0.39
Client-Related
 Higher than median number of attendees per day (> 78) 1.42 (1.04), 0.63 0.62 (0.43), 0.49 2.14 (2.02), 0.41
 Higher than median % of clients tested for HCV (> 80%) 1.98 (1.38), 0.32 0.38 (0.26), 0.15 0.51 (0.38), 0.36
 Higher than median % of clients estimated as HCV positive (> 60%) 0.83 (0.57), 0.79 0.60 (0.40), 0.44 1.00 (0.75), 1.00
Service-Related
 Provide naloxone onsite 3.02 (2.25), 0.12 1.67 (1.07), 0.42 0.49 (0.43), 0.40
 Provide HIV counselling onsite 2.57 (1.77), 0.17 4.09* (2.90), 0.04 3.36 (3.78), 0.23
 Provide HIV testing onsite 44.57*** (50.06), 0.00 7.00*** (4.75), 0.00 2.84 (2.50), 0.21
 Provide OST onsite 2.45 (2.11), 0.27 5.40* (4.62), 0.03 4.29 (3.52), 0.08
 Provide HBV vaccination onsite 7.29** (6.15), 0.01 6.67*** (4.67), 0.00 1.47 (1.15), 0.62
 Higher than median no of spaces for drug use (> 10) 0.63 (0.43), 0.49 0.62 (0.39), 0.44 2.97 (2.68), 0.21
  1. *statistically significant difference (country group vs. all other countries) on p < 0.05 level; **statistically significant difference on p < 0.01 level; ***statistically significant difference on p = 0.00 level